Opinion|Videos|February 6, 2025
Obe-Cel and MRD Outcomes: Insights and Comparisons
Panelists discuss how real-world outcomes data from the CIBMTR registry on brexucabtagene autoleucel (brexu-cel) presented at the American Society of Hematology Annual Meeting and Exposition (ASH 2024) align with clinical practice, as well as the key findings from the FELIX trial, including minimal residual disease (MRD) outcomes and comparisons with the ZUMA-3 trial for obecabtagene autoleucel (obe-cel) in relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr. O’Dwyer to Dr. Logan: There’s been a lot of real-world outcomes data with brexu-cel. Can you share some ASH 2024 data updates from CIBMTR and whether these data reflect what you have observed in your day-to-day clinical practice?
- Resource links:
ASH 2024 poster 5092, Wudhikarn K et al, brexu-cel CIMBTR registry updates , or see Appendix 2. - Dr. O’Dwyer to Dr. Molina: One of the biggest updates in ALL is the recent FDA approval of obe-cel. Can you review the FELIX trial, including study design and ASH 2024 updates on MRD outcomes? How is this trial similar and different than ZUMA-3?
Advertisement
Related to this article
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.
ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.
Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
3
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
4
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
5